Onxeo Publishes Shareholder Newsletter
(WorldNews Denmark)

Onxeo Publishes Shareholder Newsletter Onxeo Publishes Shareholder Newsletter PARIS--(BUSINESS WIRE)-- Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (`Onxeo` or `the Company `), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces the publication of its shareholder letter. In this new issue, readers will find out about Onxeo`s perspectives for 2020 and the clinical development plan of AsiDNATM, notably about an upcoming clinical study designed to evaluate the effect of AsiDNATM in combination with niraparib on the abrogation...